Professional title: Fellow in Gastroenterology
Year of primary qualification: 2006 (MD), 2013 (PhD)
Current institution: Department of Gastroenterology and Hepatology, VU University medical centre, Amsterdam, The Netherlands
Title of presentation: New, non-invasive screening tools for colonic polyps
Learning objectives: Secondary prevention, which is defined as detection and treatment of a disease which has yet to become symptomatic, aims to diagnose and treat existing disease in its early stages before it results in significant morbidity. Its high prevalence and natural history make colorectal cancer (CRC) a prime candidate for secondary prevention by means of population screening. Current population screening programs for CRC and its precursors, are using fecal occult blood tests as a preselecting tool before colonoscopy. At the end of the presentation delegates will have learned about the effectiveness of these current tests and what to expect from future screening tests.
Clinical/research background
Frank Oort is currently completing his fellowship at the Department of Gastroenterology and Hepatology of the VU University medical centre (VUmc) in Amsterdam, the Netherlands. His clinical focal point is on digestive oncology. For several years he has been active in a research group which is a collaboration between the departments of Gastroenterology and Pathology at the VUmc. His research interest focuses on population screening for colorectal cancer using non-invasive tests. In 2013 he successfully defended his PhD thesis titled: 'Survival of the FI-Test: Past, Present and Future of Fecal Immunochemical Tests in Colorectal Cancer screening'.
Relevant peer-reviewed publications
- de Boer NK, de Meij TG, Oort FA, Ben Larbi I, Mulder CJ, van Bodegraven AA, van der Schee MP. The scent of colorectal cancer: detection by volatile organic compound analysis. Clin Gastroenterol Hepatol. 2014 Jul;12(7):1085-9. doi: 10.1016/j.cgh.2014.05.005.
- van Turenhout ST, van Rossum LG, Oort FA, Laheij RJ, van Rijn AF, Terhaar sive Droste JS, Fockens P, van der Hulst RW, Bouman AA, Jansen JB, Meijer GA, Dekker E, Mulder CJ. Similar fecal immunochemical test results in screening and referral colorectal cancer. World J Gastroenterol. 2012 Oct 14;18(38):5397-403. doi: 10.3748/wjg.v18.i38.5397.
- Bosch LJ, Mongera S, Terhaar Sive Droste JS, Oort FA, van Turenhout ST, Penning MT, Louwagie J, Mulder CJ, van Engeland M, Carvalho B, Meijer GA. Analytical sensitivity and stability of DNA methylation testing in stool samples for colorectal cancer detection. Cell Oncol (Dordr). 2012 Aug;35(4):309-15. doi: 10.1007/s13402-012-0092-6. Epub 2012 Jul 21.
- Bosch LJ, Oort FA, Neerincx M, Khalid-de Bakker CA, Terhaar sive Droste JS, Melotte V, Jonkers DM, Masclee AA, Mongera S, Grooteclaes M, Louwagie J, van Criekinge W, Coupé VM, Mulder CJ, van Engeland M, Carvalho B, Meijer GA. DNA methylation of phosphatase and actin regulator 3 detects colorectal cancer in stool and complements FIT. Cancer Prev Res (Phila). 2012 Mar;5(3):464-72. doi: 10.1158/1940-6207.CAPR-11-0315. Epub 2011 Dec 1.
- Oort FA, van Turenhout ST, Coupé VM, van der Hulst RW, Wesdorp EI, Terhaar sive Droste JS, Larbi IB, Kanis SL, van Hengel E, Bouman AA, Meijer GA, Mulder CJ. Double sampling of a faecal immunochemical test is not superior to single sampling for detection of colorectal neoplasia: a colonoscopy controlled prospective cohort study. BMC Cancer. 2011 Oct 10;11:434. doi: 10.1186/1471-2407-11-434.
- Terhaar sive Droste JS, Oort FA, van der Hulst RW, van Heukelem HA, Loffeld RJ, van Turenhout ST, Ben Larbi I, Kanis SL, Neerincx M, Räkers M, Coupé VM, Bouman AA, Meijer GA, Mulder CJ. Higher fecal immunochemical test cutoff levels: lower positivity rates but still acceptable detection rates for early-stage colorectal cancers. Cancer Epidemiol Biomarkers Prev. 2011 Feb;20(2):272-80. doi: 10.1158/1055-9965.EPI-10-0848. Epub 2010 Dec 6.
- Terhaar sive Droste JS, Oort FA, van der Hulst RW, Coupé VM, Craanen ME, Meijer GA, Morsink LM, Visser O, van Wanrooij RL, Mulder CJ. Does delay in diagnosing colorectal cancer in symptomatic patients affect tumor stage and survival? A population-based observational study. BMC Cancer. 2010 Jun 28;10:332. doi: 10.1186/1471-2407-10-332.
- Oort FA, Terhaar Sive Droste JS, Van Der Hulst RW, Van Heukelem HA, Loffeld RJ, Wesdorp IC, Van Wanrooij RL, De Baaij L, Mutsaers ER, van der Reijt S, Coupe VM, Berkhof J, Bouman AA, Meijer GA, Mulder CJ. Colonoscopy-controlled intra-individual comparisons to screen relevant neoplasia: faecal immunochemical test vs. guaiac-based faecal occult blood test. Aliment Pharmacol Ther. 2010 Feb 1;31(3):432-9. doi: 10.1111/j.1365-2036.2009.04184.x. Epub 2009 Oct 29.
- Melotte V, Lentjes MH, van den Bosch SM, Hellebrekers DM, de Hoon JP, Wouters KA, Daenen KL, Partouns-Hendriks IE, Stessels F, Louwagie J, Smits KM, Weijenberg MP, Sanduleanu S, Khalid-de Bakker CA, Oort FA, Meijer GA, Jonkers DM, Herman JG, de Bruïne AP, van Engeland M. N-Myc downstream-regulated gene 4 (NDRG4): a candidate tumor suppressor gene and potential biomarker for colorectal cancer. J Natl Cancer Inst. 2009 Jul 1;101(13):916-27. doi: 10.1093/jnci/djp131. Epub 2009 Jun 17.
- Glöckner SC, Dhir M, Yi JM, McGarvey KE, Van Neste L, Louwagie J, Chan TA, Kleeberger W, de Bruïne AP, Smits KM, Khalid-de Bakker CA, Jonkers DM, Stockbrügger RW, Meijer GA, Oort FA, Iacobuzio-Donahue C, Bierau K, Herman JG, Baylin SB, Van Engeland M, Schuebel KE, Ahuja N. Methylation of TFPI2 in stool DNA: a potential novel biomarker for the detection of colorectal cancer. Cancer Res. 2009 Jun 1;69(11):4691-9. doi: 10.1158/0008-5472.CAN-08-0142. Epub 2009 May 12.
Information submitted for ESCP Barcelona 2014
